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ABSTRACT
Background. The disease course of adult immunoglobulin A (IgA) vasculitis (IgAV; Henoch–Schönlein purpura) has not been
well defined.
Methods. In a retrospective survey, we studied 85 adult IgAV patients with extended follow-up (median 43 months) for 67
patients.
Results. Only 33 of 67 (49%) achieved complete remission. Ongoing renal disease was the most common persistent organ
manifestation, but extra-renal disease activity was also present in >50% of patients not achieving complete remission.
Twenty-nine of 67 (43%) had relapsing disease, with 18/67 (27%) experiencing several relapses. Skin disease was the most
common feature in relapsing patients, followed by nephritis. At 4 years of follow-up, 6 of 29 (21%) experienced progressive
disease and 10/29 (34%) relapsing disease. Five of 67 (7%) developed nephritis after diagnosis, within the first 6 months of
follow-up. At final follow-up, 10 of 67 (15%) had chronic kidney disease Stage G3a, 18 (27%) haematuria and 13 (19%)
proteinuria. No therapy appeared particularly effective and only 6/17 patients treated with mycophenolate mofetil
experienced a good response.
Conclusions. The disease course of adult IgAV is different from that seen in children, with higher frequency of persisting and
relapsing disease. Renal disease is the main determinant of ongoing disease activity, but extra-renal features were seen in
>50% of patients with chronic disease activity. No clear conclusions on use or choice of immunosuppressive agent could be
made based on our experience.
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INTRODUCTION
Immunoglobulin A (IgA) vasculitis (IgAV), formerly Henoch–
Schönlein purpura, is a systemic small-vessel leukocytoclastic
vasculitis, caused by the deposition of IgA-containing immune
complexes. It is the most frequent systemic childhood vasculitis
(annual incidence of 6.2–24/100 000 children [1]), but is less com-
mon in adults, with an estimated annual incidence of 0.8–1.8/
100 000 patients [2], although this may be an underestimate:
Hocevar et al. [3] reported an annual incidence of 5.1/100 000
adults with biopsy-proven disease. There are no established di-
agnostic criteria for IgAV. The American College of
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Rheumatology (ACR) 1990 classification criteria [4] (Table 1)
have less utility in adults and do not differentiate well from
other small vessel vasculitides. The European League Against
Rheumatism, Paediatric Rheumatology International Trials
Organisation and Paediatric Rheumatology European Society
(EULAR/PRINTO/PRES) classification criteria [5] (Table 1) provide
classification criteria only for childhood IgAV.
IgAV is characterized by the tetrad of palpable purpura, ar-
thralgia/arthritis, gastrointestinal involvement and glomerulo-
nephritis, but not all features are necessarily present and
other organ systems can be involved. Except for life-
threatening gastrointestinal and pulmonary involvement at
initial presentation, the morbidity and mortality of IgAV are
mainly determined by the severity of renal involvement.
Palpable purpura is the most prevalent symptom, reported in
up to 100% of adults and children. Joint involvement is pre-
sent in 51–65% of adults and 67–75% of children, while gastro-
intestinal involvement is reported in 57–84% of adults and 67–
71% of children [6, 7]. Glomerulonephritis is more frequent in
adults (58–84% versus 27–56% of children), more severe (14%
of adults versus 5% of children have nephrotic syndrome, 11%
versus 4% nephritic syndrome and 13–46% versus 3–7% renal
insufficiency) [6–8] and has worse long-term renal outcome
(Table 2).
Pillebout et al. [11] reported renal insufficiency and protein-
uria >1 g/24 h at baseline, the proportion of interstitial fibrosis,
fibrinoid necrosis and glomerular sclerosis to be associated with
worse renal prognosis, while Coppo et al. [10] found proteinuria
during follow-up to be the main risk factor for the progression
of IgAV nephritis. Data regarding the disease course and extra-
renal outcome in the adult population are scarce. Relapse rates
of 14–43% have been described in children, while in adults 26–
48% of patients experience relapses [6, 11, 14]. The goal of this
retrospective study was to investigate the disease course and




We retrospectively analysed the medical records of all IgAV
patients aged 16 years, attending a vasculitis clinic at a
University Hospital, between 1 March 2004 and 31 August 2015.
The diagnosis of IgAV was made by an experienced nephrolo-
gist or rheumatologist based on clinical judgement with or
without histological confirmation. We excluded patients with
thrombocytopaenia (defined as a platelet count <150 000 109/
L), those with isolated IgA nephropathy (IgAN) and patients suf-
fering from other autoimmune diseases explaining the clinical
presentation. Ethical approval was not required for this audit re-
view under National Health Service guidelines.
Evaluation and clinical definitions
The initial clinical and laboratory presentation and the presence
of predisposing factors were evaluated. The initial presentation
was assessed for the presence of palpable purpura, joint in-
volvement (polyarthralgia and/or joint effusion), gastrointesti-
nal involvement (nausea, vomiting, abdominal pain, diarrhoea
and/or rectal bleeding), hypertension, renal involvement, con-
stitutional symptoms and other organ involvement.
Hypertension was defined as a systolic blood pressure (BP)
140 mmHg and/or diastolic BP90 mmHg and/or treatment
with antihypertensive medication prior to IgAV diagnosis. Renal
involvement was the presence of proteinuria (>30 mg/mmol al-
bumin to creatinine ratio or 1þ on urine dipstick) and/or hae-
maturia [>5 red cells per high-power field (HPF) or 2þ on
Table 1. Classification criteria for IgAV
Criterion Definition
ACR classification criteriaa
Palpable purpura Slightly raised ‘palpable’ haemorrhagic skin lesions, not related to
thrombocytopaenia
Age 20 years at disease onset Patient 20 years or younger at onset of first symptoms
Bowel angina Diffuse abdominal pain, worse after meals or the diagnosis of ischaemia, usually
including bloody diarrhoea
Wall granulocytes on biopsy Histologic changes showing granulocytes in the walls of arterioles or venules
EULAR/PRINTO/PRES classification criteriab
Purpura (mandatory) Purpura (commonly palpable and in crops) or petechiae, with lower limb pre-
dominance, not related to thrombocytopaeniac
Abdominal pain Diffuse abdominal colicky pain with acute onset assessed by history and physi-
cal examination; may include intussusception and gastrointestinal bleeding
Histopathology Typically leukocytoclastic vasculitis with predominant IgA deposits or prolifera-
tive glomerulonephritis with predominant IgA deposits
Arthritis or arthralgias Arthritis of acute onset defined as joint swelling or joint pain with limitation on
motion; arthralgia of acute onset defined as joint pain without joint swelling
or limitation on motion
Renal involvement Proteinuria >0.3 g/24 h or >30 mg/mmol of urine albumin/creatinine ratio on a
spot morning sample; haematuria or red blood cell casts: >5 red blood cells/
HPF or red blood cells casts in the urinary sediment or 2þ on dipstick
aThe presence of at least two criteria yields a sensitivity of 87.1% and a specificity of 87.7%.
bThe presence of purpura with lower limb predominance and at least one of the other four criteria yields a sensitivity of 100% and a specificity of 87%.
cFor purpura with atypical distribution a demonstration of an IgA deposit in a biopsy is required.
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dipstick] and/or new estimated glomerular filtration rate (eGFR)
[Modification of Diet in Renal Disease (MDRD) equation]
<60 mL/min/1.73 m2, further classified as acute kidney injury
(AKI) staged according to the Kidney Disease: Improving Global
Outcomes (KDIGO) criteria (Stage 1: increase in serum creatinine
to 1.5–1.9 times baseline or increase in serum creatinine by
26.5 lmol/L, Stage 2: increase in serum creatinine to 2.0–2.9
times baseline, Stage 3: increase in serum creatinine to 3.0 times
baseline or increase in serum creatinine to 353.6 lmol/L or the
initiation of renal replacement therapy). Nephrotic-range pro-
teinuria was defined as proteinuria >300 mg/mmol albumin to
creatinine ratio. The levels of C-reactive protein (CRP), erythro-
cyte sedimentation rate (ESR) and IgA were recorded.
In patients with at least 6 months of follow-up, organ in-
volvement and disease status (categorized as complete remis-
sion, partial remission, progressive disease or relapsing disease)
were evaluated at different time points (6, 12, 24, 36 and
48 months of follow-up) and relapses were recorded during
follow-up. Time to remission and time to relapse was calculated
for every patient reaching complete remission and experiencing
relapsing disease, respectively. For extra-renal disease, com-
plete remission was defined as the absence of extra-renal
symptoms with a prednisolone dose <10 mg/day, and partial re-
mission was defined as marked improvement without complete
disappearance of extra-renal symptoms with a prednisolone
dose <10 mg/day or the absence of extra-renal symptoms with
a prednisolone dose 10 mg/day. For renal disease, complete re-
mission was defined as an eGFR60 mL/min/1.73 m2 (MDRD),
proteinuria 30 mg/mmol albumin to creatinine ratio or <1þ on
dipstick and haematuria 5 red cells per HPF or <2þ on dipstick
with a prednisolone dose <10 mg/day. Partial renal remission
was defined as >50% eGFR improvement if previous eGFR was
<60 mL/min/1.73 m2 (MDRD) and proteinuria 70 mg/mmol al-
bumin to creatinine ratio or <2þ on dipstick with or without mi-
croscopic haematuria with a prednisolone dose <10 mg/day, or
as the presence of complete renal remission with a predniso-
lone dose of 10 mg/day. Progressive extra-renal disease was
defined as the lack of improvement of respective extra-renal
symptoms and progressive renal disease as the failure to
achieve partial renal remission. Relapsing disease was defined
Table 2. Long-term renal outcome in adult IgAV





Renal insufficiencya: 10% of adults, 0% of children
Persistent haematuria and/or proteinuria without renal insuf-
ficiency: 29% of adults, 11% of children
5–6 years
median
Blanco et al. [9] 38 adults
114 children
Mild renal impairmentb: 11% of adults, 0% of children
Microscopic haematuria: 0% of adults, 5% of children
12–15 months
median
Coppo et al. [10] 83 adults
136 children
biopsy-proven nephritis
Dialysis-dependency: 13% of adults, 7% of children
Severe renal impairmentc: 10% of adults, 5% of children
Moderate renal impairmentd: 15% of adults, 12% of children
Moderate proteinuria with normal renal function: 15% of
adults, 12% of children
Proteinuria 1 g/24 h with normal renal function: 40% of
adults, 45% of children
Nephrotic-range proteinuria: 2% of adults, 4% of children
4.5 years
median
Pillebout et al. [11] 250 adults
biopsy-proven nephritis
ESRD: 11%
Severe renal insufficiencye: 13%












Proteinuria with normal renal function: 19%
9.4 6 7.1 years
mean 6 SD
Rauta et al. [13] 38 adults
biopsy-proven nephritis





6.1 6 4.3 years
mean 6 SD
aPlasma creatinine>125% upper limit of normal.
bPlasma creatinine 1.6–2.4 mg/dL.
cSerum creatinine>3 mg/dL in adults and CrCl<60 mL/min/1.73 m2 (Schwartz formula) in children.
dSerum ceatinine>1.5 mg/dL and 3 mg/dL in adults, and CrCl<90 mL/min/1.73 m2 and 60 mL/min/1.73 m2 (Schwartz formula) in children.
eCrCl<30 mL/min (Cockroft and Gault formula).
fCrCl<50 mL/min and CrCl30 mL/min (Cockroft and Gault formula).
gCrCl50 mL/minþabsence of proteinuriaþabsence of haematuria.
hAbsence of extra-renal involvementþ creatinine <120 lmol/L in females, <130 lmol/L in malesþabsence of significant haematuria (1106/24 h in males, 2106/
24 h in females) and/or proteinuria (<0.3 g/24 h).
iCreatinine120 lmol/L in females, 130 lmol/L in males.
ESRD, end-stage renal disease; CrCl, creatinine clearance.
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as the recurrence of disease activity after a 1-month period of
complete or partial remission since the last evaluation time
point. Disease status was labelled as progressive, relapsing or
partial remission if a minimum of one organ system presented
with progressive disease, relapsing disease or partial remission
respectively, respecting the following order of rank: progressive
disease> relapsing disease>partial remission> complete re-
mission. Chronic kidney disease (CKD) Stage G3a was defined as
eGFR 45–59 mL/min/1.73 m2 for 3 months, Stage G3b eGFR 30–
44 mL/min/1.73 m2 for 3 months, Stage G4 eGFR 15–29 mL/min/
1.73 m2 for 3 months and Stage G5 eGFR< 15 mL/min/1.73 m2
for 3 months or requiring renal replacement therapy.
Statistical analysis
Results are expressed as numbers (percentages) for categorical
variables and as median (range) for continuous variables.
Kaplan–Meier functions were used for survival and relapse
curve calculations.
RESULTS
Patient demographics, initial presentation
and follow-up
Eighty-five patients were assessed at the time of diagnosis
(Table 3). Fifteen of 85 (17.6%) had histological evidence of IgAV
on skin biopsy (leukocytoclastic vasculitis with IgA deposition),
and 32 (37.6%) had a renal biopsy with characteristic features
(proliferative glomerulonephritis with predominant mesangial
IgA deposition). Possible predisposing drugs were ibuprofen,
adalimumab, infliximab, oral contraception (unspecified) and
sertraline in one patient each. In two, malignancy was related
to the onset of vasculitis (prostate adenocarcinoma and meta-
static sigmoid carcinoma). Median time between disease onset
and diagnosis was 1.3 months (range 0–60.8 months). Eighty-
four patients (98.8%) fulfilled EULAR/PRINTO/PRES classification
criteria and 67 (78.8%) fulfilled ACR classification criteria at di-
agnosis. Median follow-up of all patients was 27.5 months
(range 0–204.8 months), while median follow-up for 67 patients
with at least 6 months of follow-up was 42.7 months (range 6.0–
204.8 months). Sixty patients were followed for a minimum of
12 months, 46 for 24 months, 39 for 36 months and 29 for
48 months.
General disease status and outcome
Of 67 patients with at least 6 months of follow-up, 33 (49.3%)
reached complete remission, a median of 7.6 months after diag-
nosis (range 0.3–145.0 months) (Figure 1A), while 27 (40.3%)
reached partial remission, a median of 7.1 months after diagno-
sis (range 0.2–81.7 months). At 6 months of follow-up, 58 (86.6%)
were not in complete remission, while at 12 months of follow-
up this was 49 (81.7%), at 24 months 35 (76.1%), at 36 months 25
(64.1%) and finally 19 (65.5%) at 48 months of follow-up
(Figure 2). For those not achieving complete remission, extra-
renal disease was present in 37 (63.8%) at 6 months, 32 (65.3%)
at 12 months, 18 (51.4%) at 24 months, 13 (52.0%) at 36 months
and 10 (52.6%) at 48 months of follow-up (Table 4). Twenty-nine
of 67 patients (43.3%) had at least one relapse during follow-up
(Figure 1B) and in 18/67 (26.9%) there was more than one re-
lapse. Characteristics of relapse were skin involvement in 18
(62.1%) of 29 relapsing patients, nephritis in 12 (41.4%), joint in-
volvement in seven (24.1%), gastrointestinal involvement in five
(17.2%), constitutional symptoms in three (10.3%) and episcleri-
tis in one (3.4%). One patient died during follow-up, due to acute
myocardial infarction and sepsis, at the age of 51 years.
Renal involvement and outcome
Fifty-four of 67 (80.6%) patients with at least 6 months of follow-
up had renal involvement at diagnosis, while five (7.5%) devel-
oped nephritis during follow-up, a median of 1.5 months after
diagnosis (range 0.9–5.1 months). New renal involvement was
characterized by proteinuria and haematuria in three, by
Table 3. Patient demographics, predisposing factors and initial pre-
sentation (n ¼ 85)
Age at disease onset [median (range)], years 41 (16–75)










Not recorded 5 (5.9)
Predisposing factor, n (%)
Upper respiratory tract infection 39 (45.9)
Alcohol 9 (10.6)
Drug 5 (5.9)
Physical stress 5 (5.9)
Immunization 2 (2.4)
Psychological stress 2 (2.4)
Malignancy 2 (2.4)
No predisposing factor identified 33 (38.8)
Clinical presentation, n (%)
Palpable purpura 85 (100)
Ulcerative rash 10 (11.8)
Joint involvement 59 (69.4)
Gastrointestinal involvement 40 (47.1)
Renal involvement 66 (77.6)
eGFR<60 mL/min/1.73 m2 11 (12.9)
AKI Stage 1 7 (8.2)
AKI Stage 2 1 (1.2)
AKI Stage 3 3 (3.5)
Proteinuria 51 (60.0)
Nephrotic-range proteinuria 3 (3.5)
Haematuria 57 (67.1)
Macroscopic haematuria 8 (9.4)
Hypertension 35 (41.2)
Not recorded 9 (10.6)
Ear, nose and throat involvement 7 (8.2)
Pulmonary involvement 6 (7.1)
Oral mucosal ulceration 2 (2.4)
Testicular involvement 1 (1.2)
Ocular involvement 1 (1.2)
Constitutional symptoms 42 (49.4)
Laboratory examinations, n (%)
IgA>4 g/L 27 (31.8)
Not recorded 7 (9.4)
CRP>5 mg/L 43 (50.6)
Not recorded 6 (7.1)
ESR>20 mm/h 27 (31.8)
Not recorded 9 (10.6)
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isolated haematuria in one and by AKI and proteinuria in an-
other. Eight (11.9%) had no renal involvement during follow-up.
Of patients with at least 6 months of follow-up, 20 (29.9%) de-
veloped AKI, of whom 10 (14.9%) had AKI at presentation (Stage
1 in six, Stage 2 in one and Stage 3 in three patients). Only one
required renal replacement therapy. Three (4.5%) showed com-
plete resolution of their kidney function at 6 months of follow-
up, while seven (10.4%) developed CKD. Ten (14.9%) developed
AKI during follow-up (Stage 1 in eight and Stage 2 in two
patients), at a median of 9.3 months after diagnosis (range 0.9–
62.1 months). Seven (10.4%) had complete recovery of their
kidney function by the subsequent follow-up time point, while
three (4.5%) developed CKD.
At a median final follow-up of 42.7 months (range 6.0–
204.8 months) five patients (7.5%) had CKD Stage G3a, four
(6.0%) Stage G3b and one (1.5%) Stage G4, 18 (26.9%) had haema-
turia and 13 (19.4%) had proteinuria.
The characterization of renal involvement at subsequent
follow-up is summarized in Table 5.
Treatment
Of 67 patients with at least 6 months of follow-up, 51 (76.1%) re-
ceived oral glucocorticoids, 18 (26.9%) intravenous glucocorti-
coids and 29 (43.3%) additional immunosuppressive or
immunomodulatory therapy (Table 6). Mycophenolate mofetil
(MMF) or mycophenolate sodium was administered in 19
(28.4%), of whom 17 received the therapy for at least 1 month
(Figure 3). In patients in whom MMF was started during the first
6 months of follow-up, only six of 13 demonstrated a response
at 6 months and only five of 11 at 12 months. None of the
patients in whom MMF was started after 6 months of follow-up
showed a response at 12 months.
Two patients experienced relapses during treatment with
hydroxychloroquine, one relapsed during treatment with aza-
thioprine and one during treatment with colchicine. Two re-
lapsed after stopping or reducing steroid dose and one relapsed
after stopping MMF.
DISCUSSION
We aimed to describe the disease course of an unselected co-
hort of adult IgAV patients in order to highlight the frequency of
remission failure, relapse and difficulties of treatment. Renal in-
volvement was present in 88%. Complete remission was only
achieved in 35% by 4 years, lower than in previous reports [6, 9,
12] but consistent with the remission rates seen in IgAN.
Although renal involvement was the most common reason for
remission failure, extra-renal features were also present in
>50% of patients at every follow-up time point. This is a higher
rate than described in a previous report [12] where the cohort
was defined by the presence of nephritis. Relapse rate was high
at 43%, 62% of whom suffered multiple relapses, similar to pre-



























































FIGURE 1: Kaplan–Meier curves for (A) the proportion of patients achieving complete remission and (B) the proportion of patients experiencing a relapse, in patients










































Disease status at subsequent follow-up
FIGURE 2: Disease status at subsequent follow-up. m FU, months of follow-up.
Adult IgAV: refractory and relapsing disease | 1957
Current classification criteria, ACR and EULAR/PRINTO/PRES,
performed reasonably with 79% and 99% of patients meeting
the criteria, respectively, contributing to the validation of the
EULAR/PRINTO/PRES paediatric criteria in adults. An ongoing
global study, Diagnostic and Classification Criteria for Vasculitis
[15], aims to update, improve and validate primary vasculitis
classification criteria. The pattern of clinical features of our co-
hort was compatible with previous publications [6, 7, 16, 17].
Delayed development of nephritis was observed in a minority,
as previously described by Pillebout et al. [11] in adults and by
Narchi [18] in children, but not after 6 months of follow-up. This
highlights the need for ongoing clinical review in those without
nephritis at diagnosis.
Patient survival was good, with only one death during follow-
up. Long-term renal involvement was common with long-term
haematuria in 40% and proteinuria in 30%. Proteinuria has previ-
ously been shown to be a predictor of worse renal outcome [10,
11]. Fewer patients (17%) had CKD at long-term follow-up, with no
patients having Stage G5, results that are better than described in
earlier reports (Table 2) and that might indicate that although
complete remission rates are low, the use of glucocorticoids and
additional immunosuppressive or immunomodulatory therapy
may have impacted on renal progression.
Due to the highly variable clinical outcome and lack of corre-
lation between initial presentation and long-term outcome with
a substantial proportion of patients exhibiting a self-limiting
and benign disease course, prospective, randomized or even
controlled studies regarding the treatment of IgAV are scarce.
The treatment of both childhood and adult IgAV remains con-
troversial, and consensus-based recommendations have only
been formulated in the childhood population [19]. Treatment of
adult IgAV is limited to symptom control with the addition of
oral corticosteroids in persistent and moderate organ involve-
ment and other immunosuppressive agents in severe gastro-
intestinal or renal involvement. We used oral immunosuppres-
sives such as MMF to permit steroid sparing and consolidate
treatment response, but this did not appear to effectively allow
complete remission and prevent subsequent relapse in our
study. Earlier, Ren et al. [20] described the effectiveness of MMF
as a steroid-sparing agent in a retrospective analysis of 53
adults with biopsy-proven IgAV with nephritis. Overall, the effi-
cacy of treatment of adult IgAV with corticosteroids and other
immunosuppression still remains to be demonstrated [21]. The
Randomized Therapeutic Study of Steroid vs. Steroid Plus
Cyclosphosphamide for Severe Visceral Henoch-Schönlein
Purpura (CESAR) trial [22] in severe IgAV and IgAN found no
benefit of cyclophosphamide, but was underpowered. An
Table 4. Organ involvement at subsequent follow-up in patients not achieving complete remission
Organ involvement 6 m FU (n ¼ 58) 12 m FU (n ¼ 49) 24 m FU (n ¼ 35) 36 m FU (n ¼ 25) 48 m FU (n ¼ 19)
Renal 51 (87.9) 41 (83.7) 28 (80.0) 20 (80.0) 17 (89.5)
Extra-renal 37 (63.8) 32 (65.3) 18 (51.4) 13 (52.0) 10 (52.6)
Skin 31 (53.5) 24 (49.0) 14 (40.0) 8 (32.0) 7 (36.8)
Joint 23 (39.7) 20 (40.8) 15 (42.9) 12 (48.0) 10 (52.6)
Gastrointestinal 6 (10.3) 7 (14.3) 7 (20.0) 5 (20.0) 7 (36.8)
Ocular 0 (0.0) 0 (0.0) 0 (0.0) 1 (4.0) 1 (5.3)
Constitutional 8 (13.8) 8 (16.3) 5 (14.3) 4 (16.0) 4 (21.1)
Values expressed as n (%). m FU, months of follow-up.
Table 5. Renal involvement at subsequent follow-up
Renal involvement 6 m FU (n ¼ 67) 12 m FU (n ¼ 60) 24 m FU (n ¼ 46) 36 m FU (n ¼ 39) 48 m FU (n ¼ 29)
Nephritis 50 (74.6) 41 (68.3) 27 (58.7) 20 (51.3) 16 (55.2)
CKD Stage G3a 7 (10.4) 6 (10.0) 3 (6.5) 3 (7.7) 5 (17.2)
CKD Stage G3a 4 (6.0) 4 (6.7) 2 (4.4) 2 (5.1) 4 (13.8)
CKD Stage G3b 2 (3.0) 1 (1.7) 1 (2.2) 1 (2.6) 1 (3.5)
CKD Stage G4 1 (1.5) 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
CKD Stage G5 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Proteinuria 35 (52.2) 24 (40.0) 19 (41.3) 14 (35.9) 8 (27.6)
Haematuria 48 (71.6) 39 (65.0) 23 (50.0) 17 (43.6) 12 (41.4)
Values expressed as n (%). m FU, months of follow-up.
Table 6. Immunosuppressive and immunomodulatory therapy
(n ¼ 67)
Oral glucocorticoids 51 (76.1)
Intravenous glucocorticoids 18 (26.9)
MMF/mycophenolate sodium 19 (28.4)
Cyclophosphamide 9 (13.4)
Azathioprine 9 (13.4)













Values expressed as n (%).
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observational study has reported responses to rituximab [23]
and experience with other agents in adult IgAV is too small to
draw firm conclusions. The decision to start immunosuppres-
sion in IgAN, a disease that is pathophysiologically indistin-
guishable from IgAV, is currently controversial, as the
Supportive Versus Immunosuppressive Therapy for the
Treatment Of Progressive IgAN (STOP-IgAN) trial [24] found no
effect of immunosuppression on the outcome in IgAN and as
the Therapeutic Evaluation of Steroids in IgA Nephropathy
Global (TESTING) trial [25], comparing corticosteroids with pla-
cebo, was terminated early due to unacceptably high serious
adverse event rates in the group randomized to corticoste-
roids. Novel targeted therapies, including a targeted-release
formulation of budesonide [26], the spleen tyrosine kinase in-
hibitor fostamatinib (NCT02112838) and complement-directed
therapies, for example, the complement factor B inhibitor
LNP023 (NCT03373461), are being investigated in clinical trials
for IgAN and may extend to IgAV in the foreseeable future.
The limitations of our study are the retrospective nature, po-
tential selection bias for more refractory cases with greater poten-
tial for patients in stable remission being lost to follow-up or
discharged early. Another limitation is the variable length of
follow-up. Nonetheless, our findings highlight the refractory and
relapsing disease course of adult IgAV, with a minority of patients
reaching complete remission and up to 45% of patients experienc-
ing relapses. Adult IgAV patients suffer a high rate of nephritis,
which can develop after diagnosis within the first 6 months.
Although renal involvement is the main determinant of progres-
sive or relapsing disease, the persistence of extra-renal manifesta-
tions is encountered in 50% of patients, sometimes causing severe
morbidity and mortality. Our data also highlight the need for bet-
ter treatments for IgAV.
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